Wahbe L, Schultz-Coulon H-J
Klinik für Herz- und Thoraxchirurgie, Klinikum Krefeld, Krefeld, Germany.
HNO. 2007 Sep;55(9):709-15. doi: 10.1007/s00106-006-1511-7.
ACE-inhibitors are said to cause angioneurotic edema. In spite of the fact that patients with acute angioedema of the head and neck region are usually admitted to an ENT department, there is only limited information available in the otorhinolaryngological literature on the frequency, risk of recurrent episodes and clinical significance of ACE inhibitor related angioedema.
The medical histories of all patients admitted to our hospital due to acute angioneurotic edema during the period from 1 January 1988 to 31 December 2001 were reviewed. These were supplemented with the results of a standardized questionnaire filed out by the affected patients and of a non-affected control-group.
During the observation period. 121 patients were treated for acute angioneurotic edema of the head and neck region. In 34 patients (=28.1%), edema was related to permanent treatment with ACE inhibitors. The overall frequency of angioedema and the percentage of ACE inhibitor related angioedema showed a continuous increase during the study period. There was a latency from the beginning of ACE inhibitor treatment until the first manifestation of angioedema of up to 13 years. In comparison with the group of edema patients without ACE inhibitor treatment, we found a threefold risk of recurrent edema in the ACE group. Women were affected by recurrent episodes more often than men. Until now, any individual assessment of the probable risk of developing an angioneurotic edema during ACE inhibitor treatment appears to be impossible.
据说血管紧张素转换酶抑制剂(ACE 抑制剂)会引起血管性水肿。尽管头颈部急性血管性水肿患者通常会被收治到耳鼻喉科,但耳鼻喉科文献中关于 ACE 抑制剂相关性血管性水肿的发生率、复发风险及临床意义的信息有限。
回顾了 1988 年 1 月 1 日至 2001 年 12 月 31 日期间因急性血管性水肿入住我院的所有患者的病历。这些病历还补充了受影响患者填写的标准化问卷结果以及未受影响的对照组的结果。
在观察期内,121 例患者因头颈部急性血管性水肿接受治疗。34 例患者(占 28.1%)的水肿与长期使用 ACE 抑制剂治疗有关。在研究期间,血管性水肿的总体发生率及 ACE 抑制剂相关性血管性水肿的百分比持续上升。从开始使用 ACE 抑制剂治疗到血管性水肿首次出现的潜伏期长达 13 年。与未接受 ACE 抑制剂治疗的水肿患者组相比,我们发现 ACE 抑制剂组复发水肿的风险增加了两倍。女性比男性更容易出现复发。到目前为止,似乎无法对 ACE 抑制剂治疗期间发生血管性水肿的可能风险进行个体评估。